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We have read with interest the study by Vogel and colleagues showing no benefit of 
full-defragmentation vs. pulmonary vein isolation (PVI) in patients undergoing 
catheter ablation of persistent atrial fibrillation (AF)[1].   
We believe that there are some aspects deserving reflection, which may account for 
the observed lack of benefit of the full-defragmentation strategy and may lead to the 
failure of other strategies under evaluation. 
This study clearly illustrates that the population of patients with persistent AF is 
highly heterogeneous: 52 out of 205 patients (25.4%) in the initial cohort reverted to 
sinus rhythm while receiving PVI, and thus were classified by the authors as having 
PV-dependent AF. However, we cannot rule out that even among the remaining 
patients (not going back to sinus rhythm after PVI), some of them might also be 
presenting with PV-dependent AF, as after induction of AF from PV-foci, AF may self-
perpetuate in the atria even after PVI[2]. In such patients, direct-current 
cardioversion after successful PVI would likely be enough to allow long-term 
persistence of sinus rhythm, and this seemed to be the case in the vast majority of 
patients in the PVI-only group (75% among those receiving a single ablation 
procedure). Logically, there would be no benefit of additional defragmentation in 
that sub-set of patients, as may have occurred in some patients belonging to the full-
defragmentation group. The key is to try and identify such patients prospectively. 
On the other-hand, there was a second subset of patients where triggers/drivers of 
AF were not exclusively located to the PVs. In these patients, full-defragmentation 
can theoretically be of interest. However, based on the positive results observed in 
the PVI-only group it seems that patients with non-PV dependent AF were 
significantly under-represented in this CHASE-AF-cohort. Accordingly, as the authors 
acknowledge, in this population left atrial size was smaller than in most persistent AF 
studies and “short-duration persistent AF” was the rule, with most episodes lasting 
for less than a year, and time since diagnosis being less than 5 to 6 years. Atrial 
dilation and AF duration are known to be associated higher relapse rate, and thus 
likely to associate with a more resistant persistent-AF phenotype[3, 4] due to 
structural and electrical atrial remodeling which is non-PV dependent. 
Therefore, this study illustrates that persistent AF seems to comprise two completely 
different patient populations: PV-dependent and non-PV-dependent AF. Until we are 
able to clearly identify them, research on the best approach to ablate persistent AF is 
clearly compromised and all results will be very difficult to interpret. 
The current classification for AF based on symptom/episode duration is clearly 
subjective and insufficient, and this study proves it associates poorly with the 
underlying pathophysiologic mechanisms. What is required is a more comprehensive 
AF classification scheme taking into account multiple cardiovascular risk factors 
including hypertension, diabetes, structural heart disease, lipid profile, body mass 
index, as well as specific electrophysiological (e.g surface ECG parameters, 
endocardial voltage & electrogram features), and structural phenotyopes (e.g. left 
atrial pressure/compliance[5], MRI fibrosis[6] if validated across multiple centres, 
low voltage area in atrial tissue on mapping, mitral valve disease, left ventricular 
function) to facilitate stratification of AF phenotypes and identify key factors 
determining therapeutic approaches, analogous to the CHA2DS2-VAsc scoring 
system. Without such a systematic approach we will continue to compare “apples 
with oranges” and fail to assess the true impact of different catheter-based and drug 
interventions, compromising our efforts to halt the progression of this epidemic. 
International registries of outcomes incorporating agreed clinical, structural and 
electrophysiological data and documented procedural approaches would be a step in 
the right direction to develop such a scoring system to predict clinical response to 
ablation.  
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